

Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma

Information for the public

Published: 18 February 2026

www.nice.org.uk

Belantamab mafodotin (Blenrep) with pomalidomide and dexamethasone is available on the NHS as a possible treatment for multiple myeloma in adults, if:

- they have only had 1 line of treatment, which contained lenalidomide, and
- they cannot tolerate lenalidomide or the multiple myeloma has stopped responding to it.

Lines of treatment are a sequence of treatments, starting with the best option and moving to alternatives if the first does not work or the condition gets worse. Each line can be a single drug or a combination of drugs.

If you are not eligible for belantamab mafodotin but are already having it, you should be able to continue until you and your healthcare professional decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on shared decision making](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS webpage on myeloma](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Myeloma UK](#), 0800 980 3332
- [Blood Cancer UK](#), 0808 208 0888
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-9283-6